Canada Clarifies Regulatory Pathway for Low Molecular Weight Heparins

Written on:October 8, 2013
Comments are closed

Health Canada is asking generic drugmakers seeking approval of drugs containing low molecular weight heparins to use the approval pathway for subsequent entry biologics (SEB).

Source: International Pharmaceutical Regulatory Monitor


Sorry, the comment form is closed at this time.